As a cardiologist and scientist, Elizabeth Nabel has significantly influenced modern preventive medicine: Her advocacy for risk-based strategies demonstrates the power of early detection when consistently implemented. This is where high performance in daily life is determined: Those who are aware of their cardiac risks can manage them—before they impede progress. The key lies in a few precise tests that make silent dangers visible and create genuine opportunities for action.

Heart attacks typically occur when atherosclerosisthe deposition of fats and inflammation in the arterial walls progresses and a plaque ruptures. Four silent drivers accelerate this: elevated blood pressure, unfavorable blood lipids, disturbed glucose metabolism, and chronic inflammation. Blood pressure is a continuous risk factor—just slightly elevated values increase vascular load. The lipid profile measures, among others, LDL-CLow-Density Lipoprotein Cholesterol; promotes plaque formation, but additional markers like ApoBnumber of atherogenic particles or non-HDL often better reflect particle burden. In glucose metabolism, fasting glucose, HbA1c, and if necessary, an OGTTOral Glucose Tolerance Test; measures glucose processing after defined sugar intake reveal early dysregulation. CRPC-reactive protein; inflammation marker indicates systemic inflammation that makes plaques unstable. Together, these metrics shape your personal risk profile—and thus a precise prevention plan.

Persistent inflammation is not just a backdrop but a driver of heart attacks. In a large UK Biobank analysis, chronically elevated CRP was associated with a significantly higher risk of first heart attacks—those with elevated levels in two measurements had a marked increase in events, while single spikes had less predictive value ^[1]. Even with well-controlled systolic blood pressure, a "residual risk" remained when CRP was ≥2 mg/L; the risk of major cardiovascular events was higher, especially with SBP of 120–139 mmHg ^[2]. Simultaneously, lipid management that focuses solely on LDL-C overlooks individual differences and measurement inaccuracies—particularly in cases of high triglycerides. Strategies that consider markers beyond LDL-C better identify high-risk patients and can more effectively reduce events ^[3]. After a heart attack, structured glucose diagnostics reveal how much prevention is still on the table: Centers that routinely performed OGTT identified previously undetected diabetes significantly more often and initiated therapy more frequently—a clear lever against long-term consequences ^[4]. In short: Those who systematically assess inflammation, lipids, blood pressure, and glucose shift the odds—away from heart attacks and towards sustainable performance.

The 2024 ESC guidelines frame blood pressure as a continuous risk factor: Even at "elevated blood pressure" (120–139/70–89 mmHg), early prevention is recommended, depending on overall risk, sometimes even pharmacologically. The target is a systolic range of 120–129 mmHg—a clear guiding concept for high performers who aim to manage early rather than react late ^[5]. Meanwhile, lipid research is shifting the focus from a monovalent LDL-C target to biomarker-based management: Measurement inaccuracies in hypertriglyceridemia and heterogeneous therapeutic responses call for additional markers like ApoB or non-HDL to accurately assess true particle risk and navigate very low target values safely ^[3]. The inflammation block is evidenced by two UK Biobank analyses: First, elevated CRP remained surprisingly stable across repeated measurements and robustly predicted first heart attacks—significant because chronic elevation (not one-time spikes) drives risk ^[1]. Second, elevated CRP in controlled hypertensives explained part of the remaining event risk; this makes inflammation management the next prevention lever, especially when blood pressure is already optimal ^[2]. Finally, healthcare research after MI shows that structured glucose diagnostics with OGTT increase diabetes detection and escalate therapy—an organizational lever with clinical impact ^[4].

- Blood Pressure: Measure at home 3–4 times/week in the morning; align target range with your doctor to 120–129 mmHg systolic. After 3 months of lifestyle changes without achieving the target in moderate-high overall risk: consider pharmacotherapy ^[5].
- Lipids: Annually check lipid profile including LDL-C; if triglycerides are elevated or therapy is initiated, additionally request non-HDL or ApoB to manage particle risk more precisely ^[3].
- Blood Sugar: Check fasting glucose/HbA1c with risk factors (family history, overweight, hypertension, dyslipidemia); schedule OGTT for unclear values—detects silent disorders early and accelerates therapy initiation ^[4].
- Inflammation: Measure CRP twice at an interval of 3–6 months; if persistently ≥2 mg/L, plan countermeasures together with blood pressure and lipid control (weight, exercise, possibly pharmacological) ^{[1] [2]}.
- Smoking Cessation/Nicotine: Aim for complete abstinence—nicotine itself damages blood vessels and endothelium, regardless of the product (e-cigarette, heat-not-burn, pouches) ^{[6] [7]}.
- Alcohol: Clearly limit consumption; high intake drives hypertension, cardiomyopathy, and stroke risk ^[8].
- Sleep & Stress: Aim for 7–9 hours with a regular sleep routine; utilize stress monitoring via wearables and incorporate daily relaxation windows (breathing exercises, walks)—sleep and stress impact blood pressure, inflammation, and rhythm ^{[9] [10] [11]}.

Early detection is your performance multiplier: Those who systematically track blood pressure, lipids, glucose, and CRP reduce silent risks—measurable and manageable. Start this week with home blood pressure monitoring, an appointment for a laboratory profile, and a plan for sleep, exercise, and nicotine cessation. Small, consistent steps today prevent major events tomorrow.